Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 21 other studies
12,705people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
rosuvastatin at a dose of 10 mg per day
placebo
Reduced composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke−24%
Lowered composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, revascularization, heart failure, and resuscitated cardiac arrest−25%
Reported lower LDL cholesterol, no range given−26.5
randomisedthe abstract, start to end
… lipoprotein cholesterol level was 26.5% lower in the rosuvastatin …
… in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], …
… in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Low-density lipoprotein cholesterol levelrosuvastatin at a dose of 10 mg per day vs placebo
−26.5
Composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal strokerosuvastatin at a dose of 10 mg per day vs placebo
HR 0.760.64–0.91
Composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, revascularization, heart failure, and resuscitated cardiac arrestrosuvastatin at a dose of 10 mg per day vs placebo
HR 0.750.64–0.88
StatinsLipidsCardiovascular events
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.860.85 without it
← favours treatmentfavours comparator →
1 / 7